Galenus Prize 2025: Winrevair wins the joint prize in the Orphan Drugs category
The activin signaling pathway inhibitor sotatercept (Winrevair® ) from MSD Sharp & Dohme is the first-in-class drug for the treatment of pulmonary arterial hypertension, slowing the progression of the disease and improving physical performance in patients. The substance is one of two drugs to receive the Galenus of Pergamon Prize in the Orphan Drugs category.
Arzte zeitung
